['psoriasis']
['guselkumab 100 mg', 'placebo for guselkumab', 'adalimumab', 'placebo for adalimumab']

        Inclusion Criteria:

          -  Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis) at
             least 6 months before the first administration of study agent

          -  Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at
             Screening and at Baseline

          -  Have an Investigator's Global Assessment (IGA) score >=3 at Screening and at Baseline

          -  Have an involved body surface area (BSA) >=10 percent (%) at Screening and at Baseline

          -  Must be a candidate for either systemic therapy or phototherapy for psoriasis

        Exclusion Criteria:

          -  Participants with nonplaque forms of psoriasis (for example, erythrodermic, guttate,
             or pustular) or with current drug-induced psoriasis (for example, a new onset of
             psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel
             blockers, or lithium)

          -  Participants who have ever received guselkumab or adalimumab

          -  History or current signs or symptoms of severe, progressive, or uncontrolled renal,
             hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
             hematologic, rheumatologic, psychiatric, or metabolic disturbances

          -  Has any condition that, in the opinion of the investigator, would make participation
             not be in the best interest (for example, compromise the well-being) of the
             participant or that could prevent, limit, or confound the protocol-specified
             assessments

          -  Is pregnant, nursing, or planning a pregnancy (both men and women) within 5 months
             following the last administration of study drug
      